Reduction in hematopoietic stem cell numbers with in vivo drug selection can be partially abrogated by HOXB4 gene expression

This publication has 28 references indexed in Scilit:

• Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs
  Nature Reviews Cancer, 2002
• Protection and in Vivo Selection of Hematopoietic Stem Cells Using Temozolomide, O6-Benzylguanine, and an Alkyltransferase-Expressing Retroviral Vector
  Molecular Therapy, 2001
• Limiting numbers of G156A O6-methylguanine–DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection
  Blood, 2000
• Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
  Science, 2000
• In vivo selection of retrovirally transduced hematopoietic stem cells
  Nature Medicine, 1998
• Restoration of lymphocyte function in Janus Kinase 3-deficient mice by retroviral-mediated gene transfer
  Nature Medicine, 1998
• Cytokine Prestimulation as a Gene Therapy Strategy: Implications for Using the MDR1 Gene as a Dominant Selectable Marker
  Blood, 1997
• The Hematological Effects of Folate Analogs: Implications for Using the Dihydrofolate Reductase Gene forIn VivoSelection
  Human Gene Therapy, 1996
• Transfer and expression of the human multiple drug resistance gene into live mice.
  Proceedings of the National Academy of Sciences, 1992
• Selection of Drug-Resistant Bone Marrow Cells in Vivo After Retroviral Transfer of Human MDR 1
  Science, 1992